Ribomic's operating income is $-1.2B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest operating income for 4591.T is $-1.2B as of September 2026. That compares with $-1.1B in the prior-year period — down 15.9% year over year. Investors often review this figure alongside Ribomic's historical trend and sector peers before judging valuation or financial health.
Over the past year, 4591.T's operating income moved from $-1.1B to $-1.2B — a 15.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ribomic's operating scale or balance-sheet position.
A operating income figure of $-1.2B for 4591.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting 4591.T's operating income ($-1.2B), review year-over-year change from $-1.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Ribomic's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.